Global Radiotherapy Device Market Size By Type (External Beam Radiotherapy Devices, Internal Beam Radiotherapy Devices), By Application (Hospitals, Ambulatory Surgical Centres), By Region, And Segment...

The Global Radiotherapy Device Market was valued at USD 7.6 billion in 2023 and is projected to reach USD 13.4 billion by 2031, expanding at a CAGR of 7.3% during the forecast period (2023–2031). The surge in cancer incidences, rising preference for non-invasive treatment options, and growing advancements in radiotherapy technologies are significantly fueling market growth. Innovations in image-guided and adaptive radiotherapy, combined with the integration of artificial intelligence in treatment planning, are reshaping oncological care delivery across the globe.

Drivers:

1. Rising Incidence of Cancer:

The escalating global burden of cancer is the foremost driver of the radiotherapy device market. Radiotherapy remains a cornerstone of cancer treatment, with over half of all cancer patients receiving it during their treatment journey.

2. Technological Advancements:

Modern radiotherapy devices feature image guidance, real-time tumor tracking, and intensity-modulated radiation therapy (IMRT), significantly enhancing precision and clinical outcomes while minimizing damage to surrounding healthy tissue.

3. Growing Geriatric Population:

An aging population is more susceptible to cancer, driving the demand for effective and minimally invasive treatment options, such as radiotherapy.

Restraints:

1. High Installation and Maintenance Costs:

Radiotherapy equipment demands substantial initial capital investment and ongoing maintenance, which can limit adoption, particularly in low-income and resource-constrained regions.

2. Shortage of Skilled Professionals:

Effective radiotherapy requires trained oncologists, physicists, and radiographers. A global shortage of such professionals poses a challenge for market expansion, especially in developing countries.

Opportunity:

1. Expanding Healthcare Infrastructure in Emerging Economies:

Rising healthcare investments in Asia-Pacific, Latin America, and parts of Africa present immense opportunities. Governments and private sectors are increasingly equipping hospitals with radiotherapy capabilities.

2. Integration of AI and Machine Learning:

The incorporation of AI into treatment planning and workflow optimization is opening new avenues for automation, personalization, and improved clinical efficiency in radiotherapy.

Market by System Type Insights:

The Linear Accelerators (LINACs) segment dominated the market in 2023 and is projected to maintain its lead through 2031. Their versatility in delivering high-precision treatments such as IMRT and stereotactic body radiotherapy (SBRT) has driven widespread adoption. Meanwhile, Proton Therapy Systems are anticipated to witness the fastest growth due to their superior dose distribution, especially for pediatric and hard-to-treat cancers.

Market by End-use Insights:

Hospitals accounted for the largest market share in 2023, with a strong trend of radiotherapy device installations across tertiary care institutions. Cancer treatment centers are also rapidly adopting advanced systems due to rising patient volumes and specialized oncology services.

Market by Regional Insights:

North America held the largest market share in 2023, driven by a robust healthcare infrastructure, early adoption of advanced technologies, and high healthcare expenditure. However, Asia-Pacific is projected to be the fastest-growing region, fueled by increasing cancer prevalence, government funding for oncology care, and rapid technological adoption in countries like China and India.

Competitive Scenario:

Leading players in the global radiotherapy device market include Varian Medical Systems (a Siemens Healthineers company), Elekta AB, Accuray Incorporated, ViewRay Inc., and IBA (Ion Beam Applications SA). These companies are investing in R&D, strategic collaborations, and geographic expansion to strengthen their market presence.

Recent Developments:

In 2024, Varian introduced a next-generation AI-enabled treatment planning solution to accelerate radiotherapy workflows.

Elekta received regulatory clearance in 2023 for its new Unity MR-Linac system across major regions, offering adaptive radiation therapy with MRI integration.

In 2025, Accuray partnered with a leading oncology network in Asia-Pacific to deploy its CyberKnife robotic radiosurgery systems.

Scope of Work – Global Radiotherapy Device Market

Report Metric Details

Market Size (2023) USD 7.6 billion

Projected Market Size (2031) USD 13.4 billion

CAGR (2023–2031) 7.3%

Market Segments System Type (LINACs, Proton Therapy, Others), End-use (Hospitals, Cancer Centers, Others), Region

Growth Drivers Rising cancer prevalence, Technological advancements, Aging population

Opportunities Emerging market penetration, AI integration in radiotherapy

Key Market Developments:

2024: Varian launched AI-enhanced adaptive radiotherapy platforms for real-time tumor tracking.

2023: Elekta secured European CE marking for its next-gen MR-Linac.

2025: IBA announced a large-scale installation project of proton therapy systems across key Asian medical centers.

FAQs:

1. What is the current market size of the Global Radiotherapy Device Market?

The market was valued at USD 7.6 billion in 2023.

2. What is the major growth driver of the Global Radiotherapy Device Market?

The major growth driver is the rising global incidence of cancer and the demand for precise, non-invasive treatment options.

3. Which is the largest region during the forecast period in the Global Radiotherapy Device Market?

North America held the largest share in 2023, though Asia-Pacific is expected to register the fastest growth.

4. Which segment accounted for the largest market share in Global Radiotherapy Device Market?

The Linear Accelerators (LINACs) segment led the market in 2023.

5. Who are the key market players in the Global Radiotherapy Device Market?

Key players include Varian (Siemens Healthineers), Elekta AB, Accuray Inc., ViewRay Inc., and IBA.